Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases

US10683345B2 · kind B2 · utility

Assignee

• Roche Glycart AG · CH

Inventors

• Harald Duerr · Starnberg, DE
• Frank Herting · Penzberg, DE
• Christian Klein · Iffeldorf, DE
• Joerg Thomas Regula · Munich, DE
• Matthias Rueth · Penzberg, DE
• Kay-Gunnar Stubenrauch · Frauenfeld, CH

Key dates

• Filing date: May 23, 2017
• Grant date: Jun 16, 2020
• Expiry date: May 23, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.